Literature DB >> 8594638

Intraocular injection of ceftazidime. Effects of inflammation and surgery.

A Shaarawy1, T A Meredith, M Kincaid, J Dick, E Aguilar, D J Ritchie, R M Reichley.   

Abstract

OBJECTIVE: The clearance of ceftazidime from the rabbit vitreous cavity after injection into phakic, aphakic, and aphakic vitrectomized rabbit eyes was assessed and the duration of concentrations above the minimal inhibitory concentrations for target gram-negative bacteria was determined. To determine the effect of inflammation on the intraocular pharmacokinetics of ceftazidime, each anatomic group was subdivided into inflamed and control eyes.
METHODS: Ceftazidime (2.25 mg) was into the vitreous cavity of inflamed and control rabbit eyes and its concentration was assayed 2, 8, 24, and 48 hours later. The half-life for each of the anatomic groups was calculated.
RESULTS: The half-life of ceftazidime in control phakic eyes was 13.8 hours. In aphakic eyes the half-life was 11.8 hours and in the aphakic vitrectomized eyes the half-life was 4.7 hours. Inflammation slightly shortened the half-life in phakic (10.1 hours) and aphakic (8.7 hours) eyes. The half-life in aphakic vitrectomized inflamed eyes was 5.1 hours.
CONCLUSION: Vitrectomy and lensectomy significantly shorten the half-life of ceftazidime after intravitreal injection. Inflammation increases clearance to a small degree in phakic and aphakic eyes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594638

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Endophthalmitis: antibacterial activity of precipitates of vancomycin and ceftazidime.

Authors:  Kuan-Jen Chen; Tun-Lu Chen; Chi-Chun Lai; Ming-Hui Sun
Journal:  J Clin Microbiol       Date:  2008-06       Impact factor: 5.948

2.  Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery.

Authors:  Céline Faure; Daniel Perreira; Isabelle Audo
Journal:  Doc Ophthalmol       Date:  2014-10-16       Impact factor: 2.379

3.  Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls.

Authors:  John B Christoforidis; Zhiliang Xie; Angela Jiang; Jillian Wang; Cedric Pratt; Anne Gemensky-Metzler; Mahmoud Abdel-Rasoul; Sashwati Roy; Zhongfa Liu
Journal:  Curr Eye Res       Date:  2013-04-02       Impact factor: 2.424

4.  Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy.

Authors:  John B Christoforidis; Michelle M Williams; Jillian Wang; Angela Jiang; Cedric Pratt; Mahmoud Abdel-Rasoul; George H Hinkle; Michael V Knopp
Journal:  Retina       Date:  2013-05       Impact factor: 4.256

5.  Management of endophthalmitis while preserving the uninvolved crystalline lens.

Authors:  Justin Townsend; Avinash Pathengay; Harry W Flynn; Darlene Miller
Journal:  Clin Ophthalmol       Date:  2012-03-20

Review 6.  Pharmacokinetics of intravitreal antibiotics in endophthalmitis.

Authors:  Medikonda Radhika; Kopal Mithal; Abhishek Bawdekar; Vivek Dave; Animesh Jindal; Nidhi Relhan; Thomas Albini; Avinash Pathengay; Harry W Flynn
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-09-10

7.  Intracameral cefuroxime in combined pars plana vitrectomy and phacoemulsification: a study of safety.

Authors:  Gianluca Besozzi; Attilio Di Salvatore; Daniele Cardillo; Alessandro Finzi; Joseph Sajish Pinackatt; Andrea Baldi; Alessandro Monfardini; Valeria Forioli; Rino Frisina; Barbara Parolini
Journal:  Clin Ophthalmol       Date:  2018-08-28

Review 8.  A Review of Antimicrobial Therapy for Infectious Uveitis of the Posterior Segment.

Authors:  Ahmed B Sallam; Kyle A Kirkland; Richard Barry; Mohamed Kamel Soliman; Tayyeba K Ali; Sue Lightman
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2018

Review 9.  Review of Intraocular Pharmacokinetics of Anti-Infectives Commonly Used in the Treatment of Infectious Endophthalmitis.

Authors:  Andrea Luaces-Rodríguez; Miguel González-Barcia; María José Blanco-Teijeiro; María Gil-Martínez; Francisco Gonzalez; Francisco Gómez-Ulla; María-Jesús Lamas; Francisco-Javier Otero-Espinar; Anxo Fernández-Ferreiro
Journal:  Pharmaceutics       Date:  2018-05-29       Impact factor: 6.321

Review 10.  Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations.

Authors:  Rubén Varela-Fernández; Victoria Díaz-Tomé; Andrea Luaces-Rodríguez; Andrea Conde-Penedo; Xurxo García-Otero; Asteria Luzardo-Álvarez; Anxo Fernández-Ferreiro; Francisco J Otero-Espinar
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.